Your browser doesn't support javascript.
loading
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Kamrava, Mitchell R; Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Mirza, Mansoor R; McCormick, Colleen; Lorusso, Domenica; Freyer, Gilles; O'Malley, David M; York, Whitney; Malinowska, Izabela A; Monk, Bradley J.
Afiliación
  • Kamrava MR; Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: mitchell.kamrava@cshs.org.
  • Gonzalez-Martin A; Grupo Español de Investigación en Cáncer ginecológicO (GEICO) and Cancer Clínica Universidad de Navarra, Madrid, Spain.
  • Pothuri B; NYU Langone Health Perlmutter Cancer Center, New York, NY, USA.
  • Vergote I; Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Graybill W; Gynecologic Oncology Group (GOG) and Medical University of South Carolina, Charleston, SC, USA.
  • Mirza MR; Nordic Society of Gynecologic Oncology (NSGO) and Rigshositalet-Copenhagen University Hospital, Copenhagen, Denmark.
  • McCormick C; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
  • Lorusso D; Director of Gynecologic Oncology Unit Humanitas San Pio X Milan and Full Professor of Obstetrics and Gynecology Humanitas University Rozzano (MI), Milan, Italy.
  • Freyer G; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens and Centre Hospitalier Lyon-Sud, Lyon, France.
  • O'Malley DM; The Ohio State University and The James Comprehensive Cancer Center, Columbus, OH, USA.
  • York W; GSK, Philadelphia, PA, USA.
  • Malinowska IA; GSK, Philadelphia, PA, USA.
  • Monk BJ; Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA.
Gynecol Oncol ; 189: 68-74, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39032397
ABSTRACT

OBJECTIVES:

Patterns of disease recurrence on poly(ADP-ribose) polymerase inhibitor maintenance therapy are unclear and may affect subsequent treatment. This ad hoc subgroup analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 study evaluated patterns of initial recurrence in patients with advanced ovarian cancer (AOC).

METHODS:

PRIMA included participants at high risk for disease progression. This ad hoc analysis only evaluated participants randomized to niraparib maintenance without evidence of disease at baseline. The number and site(s) of initial recurrent lesions at investigator-assessed progressive disease (PD) were evaluated.

RESULTS:

Of the 314 niraparib-treated patients analyzed, 190 developed ≥1 new lesion (median number of new lesions, 1.0; interquartile range, 1-2). In total, 93.2% (177/190) of patients developed 1-3 lesions at first disease progression. The most common sites of recurrence were the peritoneum (30.0% [57/190]), lymph nodes (26.3% [50/190]), and liver (20.5% [39/190]). Similar results were observed when patients with PD were stratified by biomarker status, disease stage at diagnosis, and type of debulking surgery. Patients with homologous recombination-proficient tumors, stage III disease, or a history of primary debulking developed a median of 2.0 new lesions at first progression; patients with homologous recombination-deficient tumors, stage IV disease, or a history of interval debulking developed a median of 1.0 new lesion.

CONCLUSIONS:

Many patients with AOC without lesions at first-line maintenance treatment initiation develop oligometastatic disease at first recurrence. Prospective evaluation is required to determine whether these patients have improved outcomes when local therapies are combined with continuous, systemic, targeted maintenance therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Piperidinas / Quimioterapia de Mantención / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Indazoles / Recurrencia Local de Neoplasia Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Piperidinas / Quimioterapia de Mantención / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Indazoles / Recurrencia Local de Neoplasia Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos